MITHIC FL1 Mosunetuzumab
MITHIC-FL1: Phase II Study of Single-Agent Mosunetuzumab in Patients With Newly Diagnosed Follicular Lymphoma

Released: December 09, 2024

Expiration: December 08, 2025

Activity

Progress
1
Course Completed